首页 > 最新文献

Meniere's Disease [Working Title]最新文献

英文 中文
Meniere’s Disease: Nonsurgical Treatment 梅尼埃氏病:非手术治疗
Pub Date : 2019-12-13 DOI: 10.5772/intechopen.85573
Y. Yılmaz, B. Yilmaz, A. Batıoğlu-Karaaltın
Meniere ’ s disease or syndrome is one of the most common inner ear diseases. Meniere ’ s disease is characterized by episodic vertigo, sensorineural hearing loss that fluctuates during episodes, tinnitus, and ear fullness. Ideal treatment should stop vertigo attacks, restore hearing, get rid of tinnitus and ear fullness. Treatment options are decided upon the remaining hearing, severity, and intensity of vertigo attacks. Meniere ’ s disease is progressive on hearing levels of the patient; some of them develop profound hearing loss that also could affect the other ear. In order to plan a treatment scheme for patient, these conditions should be assessed. It has a destructive and progressive nature, so the first step of treatment should contain more conservative treatment options. If symptom control could not be obtained, destructive treatment options should be considered. evoked myogenic potentials show altered tuning in patients with Ménière ’ s disease.
梅尼埃氏病或综合征是最常见的内耳疾病之一。梅尼埃氏病的特点是发作性眩晕,感觉神经性听力损失,在发作期间波动,耳鸣和耳朵充血。理想的治疗应该是停止眩晕发作,恢复听力,消除耳鸣和耳朵充盈。治疗方案取决于剩余的听力、严重程度和眩晕发作的强度。梅尼埃氏病对患者的听力水平是进行性的;他们中的一些人会出现严重的听力损失,这也会影响到另一只耳朵。为了为患者制定治疗方案,应对这些情况进行评估。它具有破坏性和进行性,因此治疗的第一步应包含更多的保守治疗方案。如果无法控制症状,则应考虑破坏性治疗方案。诱发肌原电位显示在患有msamimni病的患者中发生了改变。
{"title":"Meniere’s Disease: Nonsurgical Treatment","authors":"Y. Yılmaz, B. Yilmaz, A. Batıoğlu-Karaaltın","doi":"10.5772/intechopen.85573","DOIUrl":"https://doi.org/10.5772/intechopen.85573","url":null,"abstract":"Meniere ’ s disease or syndrome is one of the most common inner ear diseases. Meniere ’ s disease is characterized by episodic vertigo, sensorineural hearing loss that fluctuates during episodes, tinnitus, and ear fullness. Ideal treatment should stop vertigo attacks, restore hearing, get rid of tinnitus and ear fullness. Treatment options are decided upon the remaining hearing, severity, and intensity of vertigo attacks. Meniere ’ s disease is progressive on hearing levels of the patient; some of them develop profound hearing loss that also could affect the other ear. In order to plan a treatment scheme for patient, these conditions should be assessed. It has a destructive and progressive nature, so the first step of treatment should contain more conservative treatment options. If symptom control could not be obtained, destructive treatment options should be considered. evoked myogenic potentials show altered tuning in patients with Ménière ’ s disease.","PeriodicalId":201520,"journal":{"name":"Meniere's Disease [Working Title]","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122220222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menière’s Disease: Etiopathogenesis 梅氏病:发病机制
Pub Date : 2019-10-23 DOI: 10.5772/intechopen.84698
Carlos A. Oliveira
This chapter will discuss idiopathic Menière’s syndrome. That is to say—Menière’s disease. We will start with a brief recall on the History of Menière’s disease beginning with the description of the syndrome by Prosper Menière in 1861, the description of endolymphatic hydrops in temporal bone studies by Hallpike and Cairns in 1938 and by Yamakaua in the same year. Endolymphatic hydrops became a pathologic correlate for Menière’s syndrome. Theories that considered endolymphatic hydrops as the cause of the syndrome will be discussed. More recent studies ques-tioning the old theories and thinking of endolymphatic hydrops as an epiphenomenon in the course of the syndrome rather than the cause of the symptoms will be discussed. Temporal bone studies were the basis of these new theories too. Familial Menière’s disease will be discussed and several families will be described in detail. Because the phenotype of siblings on each family studied was variable and migraine was present in many affected members of these families a spectrum was postulated going from migraine alone to full blown Menière’s disease. Some siblings had what has been described recently as vertiginous migraine and a detailed description of this syndrome will be provided and the differences between this syndrome and Menière’s disease will be made clear. About 20% of Menière’s disease patients have a familial history. Sporadic Meniere’s disease might have a genetic predisposition and other environmental and behavioral factors contribute for the surfacing of the disease (multifactorial etiology). Because migraine is a central phenomenon and the vertiginous episodes and auditory symptoms are peripheral a hypothesis is presented for the pathophysiology of Menière’s disease. Recent research comparing vestibular migraine and Manière’s disease reinforcing the concept of these syndromes repre-senting a continuum process with similar etiology are discussed at the end.
本章将讨论特发性meni综合征。这就是说——梅尼安德雷病。我们先简单回顾一下梅尼特病的历史从1861年Prosper meni特对综合症的描述开始,从1938年Hallpike和Cairns对颞骨内淋巴水肿的描述以及同年Yamakaua对颞骨内淋巴水肿的描述。内淋巴积液成为meni综合征的病理相关。认为内淋巴积液是该综合征的原因的理论将被讨论。更近期的研究,质疑旧的理论和思维的内淋巴积液是一个附带现象,在综合征的过程中,而不是症状的原因将被讨论。颞骨研究也是这些新理论的基础。将讨论家族性梅氏病,并详细描述几个家族。由于研究的每个家庭的兄弟姐妹的表型是可变的,并且偏头痛在这些家庭的许多受影响的成员中都存在,因此假设从单独的偏头痛到完全的梅尼氏病。一些兄弟姐妹最近被描述为眩晕性偏头痛,将提供对这种综合征的详细描述,并明确这种综合征与meni re病之间的区别。约20%的meni氏病患者有家族病史。散发性梅尼埃病可能具有遗传易感性,其他环境和行为因素也可能导致疾病的出现(多因素病因学)。由于偏头痛是中心现象,眩晕发作和听觉症状是外围现象,因此提出了meni病的病理生理学假说。最近的研究比较前庭偏头痛和maniires病加强这些症状的概念,代表一个连续的过程与相似的病因进行了讨论。
{"title":"Menière’s Disease: Etiopathogenesis","authors":"Carlos A. Oliveira","doi":"10.5772/intechopen.84698","DOIUrl":"https://doi.org/10.5772/intechopen.84698","url":null,"abstract":"This chapter will discuss idiopathic Menière’s syndrome. That is to say—Menière’s disease. We will start with a brief recall on the History of Menière’s disease beginning with the description of the syndrome by Prosper Menière in 1861, the description of endolymphatic hydrops in temporal bone studies by Hallpike and Cairns in 1938 and by Yamakaua in the same year. Endolymphatic hydrops became a pathologic correlate for Menière’s syndrome. Theories that considered endolymphatic hydrops as the cause of the syndrome will be discussed. More recent studies ques-tioning the old theories and thinking of endolymphatic hydrops as an epiphenomenon in the course of the syndrome rather than the cause of the symptoms will be discussed. Temporal bone studies were the basis of these new theories too. Familial Menière’s disease will be discussed and several families will be described in detail. Because the phenotype of siblings on each family studied was variable and migraine was present in many affected members of these families a spectrum was postulated going from migraine alone to full blown Menière’s disease. Some siblings had what has been described recently as vertiginous migraine and a detailed description of this syndrome will be provided and the differences between this syndrome and Menière’s disease will be made clear. About 20% of Menière’s disease patients have a familial history. Sporadic Meniere’s disease might have a genetic predisposition and other environmental and behavioral factors contribute for the surfacing of the disease (multifactorial etiology). Because migraine is a central phenomenon and the vertiginous episodes and auditory symptoms are peripheral a hypothesis is presented for the pathophysiology of Menière’s disease. Recent research comparing vestibular migraine and Manière’s disease reinforcing the concept of these syndromes repre-senting a continuum process with similar etiology are discussed at the end.","PeriodicalId":201520,"journal":{"name":"Meniere's Disease [Working Title]","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129888914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Procedures for Ménière’s Disease msamniires病的外科治疗
Pub Date : 2019-08-12 DOI: 10.5772/INTECHOPEN.88014
R. Bento, P. Lopes
The aim of this chapter is to present a literature review on some of the main articles describing different interventions for the treatment in patients with pro-gressive intractable Ménière disease symptoms. Even though each paper presents good results in defending its techniques, there have been few well-designed clinical studies, that is, studies involving control groups or long-term observation, in the efficacy of surgery with respect to vertigo control and hearing preservation. Focusing on presenting the different techniques established in the literature, we dis-cuss the main indications and results obtained regarding the control of vertigo and the audiological outcomes after the procedure. Physicians should offer additional treatment strategies for Meniere’s disease patients with a long history of limiting symptoms or associated hearing loss. The surgical options for such patients should be considered carefully because surgery can damage the ipsilateral ear and the hearing function of the contralateral ear is often suboptimal. Its importance is that alternatives for treatment can only be offered to a patient when doctor knows them.
本章的目的是对一些主要文章进行文献综述,这些文章描述了治疗进行性难治性msamni病症状的不同干预措施。尽管每篇论文在捍卫其技术方面都有很好的结果,但很少有精心设计的临床研究,即涉及对照组或长期观察的研究,研究手术在眩晕控制和听力保护方面的疗效。重点介绍文献中建立的不同技术,我们讨论了关于眩晕控制和手术后听力学结果的主要适应症和结果。对于有长期局限性症状或相关听力损失病史的梅尼埃病患者,医生应提供额外的治疗策略。此类患者的手术选择应慎重考虑,因为手术可损伤同侧耳,而对侧耳的听力功能通常不佳。它的重要性在于,只有在医生了解的情况下,才能向患者提供其他治疗方案。
{"title":"Surgical Procedures for Ménière’s Disease","authors":"R. Bento, P. Lopes","doi":"10.5772/INTECHOPEN.88014","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.88014","url":null,"abstract":"The aim of this chapter is to present a literature review on some of the main articles describing different interventions for the treatment in patients with pro-gressive intractable Ménière disease symptoms. Even though each paper presents good results in defending its techniques, there have been few well-designed clinical studies, that is, studies involving control groups or long-term observation, in the efficacy of surgery with respect to vertigo control and hearing preservation. Focusing on presenting the different techniques established in the literature, we dis-cuss the main indications and results obtained regarding the control of vertigo and the audiological outcomes after the procedure. Physicians should offer additional treatment strategies for Meniere’s disease patients with a long history of limiting symptoms or associated hearing loss. The surgical options for such patients should be considered carefully because surgery can damage the ipsilateral ear and the hearing function of the contralateral ear is often suboptimal. Its importance is that alternatives for treatment can only be offered to a patient when doctor knows them.","PeriodicalId":201520,"journal":{"name":"Meniere's Disease [Working Title]","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134189872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratympanic Gentamicin Treatment for Ménière’s Disease 鼓室内庆大霉素治疗msamniires病
Pub Date : 2019-06-10 DOI: 10.5772/INTECHOPEN.86790
Y. Chai, Hongzhe Li
Ménière’s disease (MD) is an inner-ear disease mostly characterized by frequent spontaneous vertigo and fluctuating sensorineural hearing loss. The main purpose of treatment for MD is to reduce or control the vertigo while maximizing the preservation of hearing. Among the various treatments, one that is effective for refractory MD, intratympanic gentamicin (ITG), relies on its ototoxic property to effectively control the vertigo symptoms of most patients. ITG treatment has relatively few side effects compared with surgically destructive treatments, but it also carries a nonnegligible risk of sensorineural hearing loss. So far, there is no consensus on the dosage and treatment duration of ITG. Most researchers recommend that intratympanic injection of gentamicin is more suitable for patients with unilateral onset and impaired hearing function, who are younger than 65 years old, as well as with frequent and severe vertigo attacks, and ineffective prior conservative treatment. Before an ITG treatment, patients should be adequately informed about the risk of hearing loss, and in order to reduce the risk of deafness, low drug dose and long intervals between injections are recommended. In short, to administer an ITG injection, multiple factors should be comprehensively considered including patient selection, pharmacological mechanism, drug dose, the interval of administration, complications, indications, and contraindications.
msamni病(MD)是一种内耳疾病,其主要特征是频繁的自发性眩晕和波动感音神经性听力损失。MD治疗的主要目的是减少或控制眩晕,同时最大限度地保护听力。在各种治疗方法中,对难治性MD有效的一种方法是鼓腔内庆大霉素(ITG),它依靠其耳毒性来有效控制大多数患者的眩晕症状。与手术破坏性治疗相比,ITG治疗的副作用相对较少,但它也有不可忽视的感觉神经性听力损失的风险。到目前为止,对于ITG的剂量和治疗时间尚无共识。大多数研究者建议鼓室内注射庆大霉素更适用于单侧发病、听力功能受损、年龄小于65岁、眩晕发作频繁且严重、既往保守治疗无效的患者。在进行ITG治疗之前,应充分告知患者听力损失的风险,为了降低耳聋风险,建议采用低剂量和长注射间隔的药物。总之,ITG注射需要综合考虑患者选择、药理机制、给药剂量、给药间隔、并发症、适应症、禁忌症等因素。
{"title":"Intratympanic Gentamicin Treatment for Ménière’s Disease","authors":"Y. Chai, Hongzhe Li","doi":"10.5772/INTECHOPEN.86790","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.86790","url":null,"abstract":"Ménière’s disease (MD) is an inner-ear disease mostly characterized by frequent spontaneous vertigo and fluctuating sensorineural hearing loss. The main purpose of treatment for MD is to reduce or control the vertigo while maximizing the preservation of hearing. Among the various treatments, one that is effective for refractory MD, intratympanic gentamicin (ITG), relies on its ototoxic property to effectively control the vertigo symptoms of most patients. ITG treatment has relatively few side effects compared with surgically destructive treatments, but it also carries a nonnegligible risk of sensorineural hearing loss. So far, there is no consensus on the dosage and treatment duration of ITG. Most researchers recommend that intratympanic injection of gentamicin is more suitable for patients with unilateral onset and impaired hearing function, who are younger than 65 years old, as well as with frequent and severe vertigo attacks, and ineffective prior conservative treatment. Before an ITG treatment, patients should be adequately informed about the risk of hearing loss, and in order to reduce the risk of deafness, low drug dose and long intervals between injections are recommended. In short, to administer an ITG injection, multiple factors should be comprehensively considered including patient selection, pharmacological mechanism, drug dose, the interval of administration, complications, indications, and contraindications.","PeriodicalId":201520,"journal":{"name":"Meniere's Disease [Working Title]","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130225454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Treatment of Meniere’s Disease by the Intratympanic Therapy 鼓室内疗法治疗梅尼埃病
Pub Date : 2019-03-01 DOI: 10.5772/INTECHOPEN.84752
Maria Stella Arantes do Amaral, H. Pauna, A. C. Reis, M. Hyppolito
Meniere’s disease represents one of the most frequent vestibulopathy, with prevalence of 46–200 cases per 100,000, without difference between genders and manifests in fourth decade of life. Features include dizziness/vertigo, hearing loss, tinnitus, and ear fullness. Individuals with Meniere’s disease have poor quality of life due to dizziness, regarding physical, functional, and emotional aspects. The thera-peutic measures are proposed, depending on the stage of the disease. About 95% of the patients are well controlled with conservative clinical treatment. The remaining 5% have incapacitating symptoms. These patients are candidates for surgical treatments classics, decompression of the endolymphatic sac, vestibular neurectomy, or labyrinthectomy. Intratympanic gentamicin injections emerged as an alternative to surgical treatments, whose risk and benefit ratio has been shown to be much more satisfactory. Aminoglycosides, such as gentamicin have been used since the decade of 1950 for the vestibular chemical ablation in cases of intractable vertigo. The drawback is that gentamicin causes irreversible destruction to cochlear hair cells with hearing loss. The selective vestibulotoxicity in the treatment of Meniere’s disease can be used in the treatment of the vertigo promoting a chemical labyrinthectomy.
梅尼埃氏病是最常见的前庭病变之一,发病率为每10万人46-200例,无性别差异,在生命的第四个十年表现出来。症状包括头晕/眩晕、听力丧失、耳鸣和耳朵充盈。患有梅尼埃氏病的人由于身体、功能和情感方面的头晕而生活质量较差。根据疾病的阶段提出了治疗措施。经保守治疗,95%左右的患者病情得到很好的控制。剩下的5%有丧失行为能力的症状。这些患者适合手术治疗,如内淋巴囊减压、前庭神经切除术或迷路切除术。鼓室内庆大霉素注射作为外科治疗的替代方案出现,其风险和效益比已被证明要令人满意得多。氨基糖苷类药物,如庆大霉素,自1950年以来已被用于治疗顽固性眩晕的前庭化学消融。其缺点是庆大霉素会对耳蜗毛细胞造成不可逆转的破坏。选择性前庭毒性治疗梅尼埃病可用于眩晕的治疗,促进化学迷路切除术。
{"title":"The Treatment of Meniere’s Disease by the Intratympanic Therapy","authors":"Maria Stella Arantes do Amaral, H. Pauna, A. C. Reis, M. Hyppolito","doi":"10.5772/INTECHOPEN.84752","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.84752","url":null,"abstract":"Meniere’s disease represents one of the most frequent vestibulopathy, with prevalence of 46–200 cases per 100,000, without difference between genders and manifests in fourth decade of life. Features include dizziness/vertigo, hearing loss, tinnitus, and ear fullness. Individuals with Meniere’s disease have poor quality of life due to dizziness, regarding physical, functional, and emotional aspects. The thera-peutic measures are proposed, depending on the stage of the disease. About 95% of the patients are well controlled with conservative clinical treatment. The remaining 5% have incapacitating symptoms. These patients are candidates for surgical treatments classics, decompression of the endolymphatic sac, vestibular neurectomy, or labyrinthectomy. Intratympanic gentamicin injections emerged as an alternative to surgical treatments, whose risk and benefit ratio has been shown to be much more satisfactory. Aminoglycosides, such as gentamicin have been used since the decade of 1950 for the vestibular chemical ablation in cases of intractable vertigo. The drawback is that gentamicin causes irreversible destruction to cochlear hair cells with hearing loss. The selective vestibulotoxicity in the treatment of Meniere’s disease can be used in the treatment of the vertigo promoting a chemical labyrinthectomy.","PeriodicalId":201520,"journal":{"name":"Meniere's Disease [Working Title]","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122986262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Meniere's Disease [Working Title]
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1